Patents Issued in October 4, 2018
-
Publication number: 20180280286Abstract: The present invention relates to a cosmetic treatment and processes for treating keratinous materials, in particular for altering the color of hair as in hair coloration, hair color lightening or removal, and treatment of artificially colored hair, wherein the composition can include at least one antioxidant, applied separately or combined or combinable with one or more components of a color altering system in amounts sufficient to confer protection when the treatment composition is applied to keratinous material and thereby enhance and protect one or more sensorial features, and preserve the mechanical properties and native amino acid structure of the keratinous material.Type: ApplicationFiled: March 31, 2017Publication date: October 4, 2018Inventors: Andrea ELSEN-WAHRER, Jim SINGER, Paul BONVALLET, Zhi PAN
-
Publication number: 20180280287Abstract: A method and composition for non-invasive treatment of skin aging conditions utilizes a topically applied composition that includes a sustainable non GMO water based extract of peptide Sacha Inchi (hydrolyzed Plukenetia Volubilis Seed Extract). The composition utilizes Sacha Inchi to clinically and non-invasively reduce after only 28 days skin sagginess and facial volume contour. Reshaping and resculpting facial skin and reducing dermal non-echogenic surfaces are also accomplished. Increased echogenic surfaces, increased dermal connective tissue and dermal density by restructuring, re-densifying and revitalizing dermis for healthier skin is furthered. The composition was clinically proven to reduce after only 21 days of treatment fine lines, deep wrinkles and facial skin roughness, for a smoother, healthier, younger and less wrinkled skin.Type: ApplicationFiled: March 6, 2018Publication date: October 4, 2018Inventors: Mihaela Gorcea, Dmitri Ptchelintsev
-
Publication number: 20180280288Abstract: A composition for whitening teeth including cocos nucifera, turmeric extract. The composition further includes sodium bicarbonate, aqua, glycerin, sodium pyrophosphate, mentha piperita, xantham gum, polysorbate-20, potassium sorbate, and sodium benzoate. The turmeric extract is configured to allow the composition to be white in color. The composition is a natural and safe teeth whitener.Type: ApplicationFiled: April 3, 2018Publication date: October 4, 2018Inventor: Drew Hamilton
-
Publication number: 20180280289Abstract: The present disclosure provides pharmaceutical compositions and processes for making solid dosage form pharmaceutical compositions that provide immediate release of active ingredients and have abuse deterrent properties. The pharmaceutical compositions provided herein comprise at least one pharmaceutically active ingredient, at least one low molecular weight hydrophilic polymer, at least one high molecular weight hydrophilic polymer, and an effervescent system.Type: ApplicationFiled: June 7, 2018Publication date: October 4, 2018Inventors: Siva N. Raman, Jae Han Park, Thomas A. Diezi, Clifford J. Herman, Sunil K. Battu, Eric A. Burge
-
Publication number: 20180280290Abstract: Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.Type: ApplicationFiled: May 11, 2018Publication date: October 4, 2018Inventors: Alexey Popov, Elizabeth M. Enlow, Hongming Chen, James Bourassa
-
Publication number: 20180280291Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions.Type: ApplicationFiled: June 4, 2018Publication date: October 4, 2018Inventor: Herriot Tabuteau
-
Publication number: 20180280292Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.Type: ApplicationFiled: June 6, 2018Publication date: October 4, 2018Applicant: Entera Bio Ltd.Inventors: Miriam KIDRON, Ehud ARBIT
-
Publication number: 20180280293Abstract: Disclosed herein is a pharmaceutical composition for skin that is a preparation containing a vitamin D3 compound and a corticosteroid as active ingredients, that is excellent in the stability of each of the active ingredients, and that has appropriate transdermal absorbability of the active ingredients. The composition is a non-aqueous composition for skin comprising: (a) maxacalcitol; (b) at least one corticosteroid selected from the group consisting of betamethasone and esters thereof; (c) at least one low-polarity ester oil having an IOB value of 0.07 or more but less than 0.20; and (d) at least one non-polar liquid solvent.Type: ApplicationFiled: November 17, 2015Publication date: October 4, 2018Inventors: Hidetoshi EMI, Masahiro FUJII
-
Publication number: 20180280294Abstract: A therapeutic putty for use in treating patients who have hand maladies and which helps alleviate the patient's pain when undergoing hand therapeutic exercises includes a silicone putty base and at least one of an analgesic and a counterirritant as an ingredient thereof and mixed with the silicone putty base.Type: ApplicationFiled: March 27, 2018Publication date: October 4, 2018Inventors: M. Gregory Minuto, Stephen Mlcoch
-
Publication number: 20180280295Abstract: The present inventions relate to pharmaceutical formulations and formulation process comprising cabazitaxel in a single vial ready to use configuration with increased stability. The stable Cabazitaxel is ready to be added directly to the infusion solution, without any need for preparing premix solutions.Type: ApplicationFiled: March 14, 2016Publication date: October 4, 2018Inventors: SONG LIN, INDU JAVERI, KALIAPPANADAR NELLAJAPPAN
-
Publication number: 20180280296Abstract: A stable high-water-content W/O-type emulsion gel comprising: a gelator composed of a compound of Formula (1) or (2) below (wherein, R1 and R3 are each independently a linear or branched alkyl group having a carbon atom number of 1 to 20, a cyclic alkyl group having a carbon atom number of 3 to 20, or a linear or branched alkenyl group having a carbon atom number of 2 to 20, n is an integer of 0 or 1 to 4, R2 is a hydrogen atom, a linear or branched alkyl group having a carbon atom number of 1 to 10, or an aryl group optionally having a substituent, and R4 and R5 are a hydroxyl group); a surfactant; and a mixed solvent of a hydrophobic organic solvent and water, wherein the content of the gelator is 0.1-20% by mass with respect to the mass of the mixed solvent.Type: ApplicationFiled: August 25, 2016Publication date: October 4, 2018Applicants: NISSAN CHEMICAL INDUSTRIES, LTD., KYUSHU UNIVERSITY, INSTITUTE OF SYSTEMS, INFORMATION TECHNOLOGIES AND NANOTECHNOLOGIESInventors: Koichiro SARUHASHI, Osamu HIRATA, Fumiyasu ONO, Seiji SHINKAI, Tatsuhiro YAMAMOTO
-
Publication number: 20180280297Abstract: A self-foaming composition is described that includes trifarotene, for a no-rinse topical application and for application to the skin. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and trifarotene or one of the pharmaceutically acceptable salts thereof being present in at least one of the intermediate compositions A and B. The composition is particularly intended for the treatment of acne. Also described is a kit or a single container including a plurality of compartments including such a composition.Type: ApplicationFiled: September 27, 2016Publication date: October 4, 2018Inventors: Jean-Christophe BUGE, Karine NADAU-FOURCADE
-
Publication number: 20180280298Abstract: A self-foaming composition is described that includes trifarotene, for a no-rinse topical application. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and trifarotene or one of the pharmaceutically acceptable salts thereof being present in at least one of the intermediate compositions A and B. The composition is particularly intended for the treatment of ichthyosis. Also described, is a kit or a single container including a plurality of compartments including such a composition.Type: ApplicationFiled: September 27, 2016Publication date: October 4, 2018Inventors: Jean-Christophe BUGE, Karine NADAU-FOURCADE
-
Publication number: 20180280299Abstract: A self-foaming composition for a topical application is described. The composition can include a medium which is cosmetically- or pharmaceutically-compatible with a topical application, and clobetasol propionate. The composition can include a small quantity of foaming surfactants. The composition includes: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and clobetasol propionate being present in at least one of the intermediate compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition.Type: ApplicationFiled: September 27, 2016Publication date: October 4, 2018Inventors: Jean-Christophe BUGE, Karine NADAU-FOURCADE
-
Publication number: 20180280300Abstract: An object of the present invention is to provide a method for encapsulating a poorly water-soluble pharmacologically active substance in a liposome with high efficiency. The present invention provides a composition comprising a lipid having a phosphatidylcholine group, a cholesterol compound, a lipid having a phosphatidylethanolamine group, and a poorly water-soluble pharmacologically active substance, wherein the molar ratio of the lipid having a phosphatidylcholine group, the cholesterol compound, the lipid having a phosphatidylethanolamine group, and the poorly water-soluble pharmacologically active substance is 3 to 8:2 to 7:0.1 to 3:0.001 to 5, respectively.Type: ApplicationFiled: October 6, 2016Publication date: October 4, 2018Applicants: ENSUIKO SUGAR REFINING CO., LTD., National University Corporation Okayama UniversityInventors: Hiroki HAMADA, Masaharu SENO, Tomonari KASAI, Tsukasa SHIGEHIRO, Koji HARA, Tetsuya ITO, Ichiro FUJIWARA
-
Publication number: 20180280301Abstract: In one aspect, the present invention provides sterile microparticle compositions comprising biodegradable microparticles, which comprise at least one biodegradable polymer. In other aspects, the present invention provides methods of making and using such compositions as well as articles of manufacture and kits containing the same.Type: ApplicationFiled: May 16, 2018Publication date: October 4, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS, SAInventors: Derek O'Hagan, Manmohan Singh, Siddhartha Jain, Padma Malyala
-
Publication number: 20180280302Abstract: The present invention refers to a method for producing storage-stable solid dispersions of poorly soluble pharmaceutically active compounds comprising polyvinyl alcohol as carrier matrix. The invention also refers to the prepared compositions and their use.Type: ApplicationFiled: December 22, 2015Publication date: October 4, 2018Applicant: MERCK PATENT GMBHInventors: Shawn KUCERA, Dieter LUBDA, Dave MILLER, Chris BROUGH
-
Publication number: 20180280303Abstract: A mesosilicalite nanocarrier having a hierarchical silicalite characterized by a molar ratio of aluminum to silica in a range of 1:3000 to 1:1000. The hierarchical silicalite includes mesopores of a hexagonal structure, and micropores of silicalite structure with a microporous volume in the range of 0.05 cc/g to 0.1 cc/g. The nanocarrier has a mesophase content in the range of 30 wt % to 70 wt %, a microphase content in the range of 30 wt % to 70 wt %, and a mean pore diameter in the range of 1.5 nm to 5.5 nm. A method of preparing the stable mesosilicalite nanocarrier with hierarchical micro/mesopores to load an antioxidant or drug for targeted drug delivery is also described.Type: ApplicationFiled: April 4, 2017Publication date: October 4, 2018Applicant: Imam Abdulrahman Bin Faisal UniversityInventors: B. Rabindran JERMY, Vijaya Ravinayagam
-
Publication number: 20180280304Abstract: The present invention provides a composite granulated product that is optimal for allowing a tablet, preferably an orally disintegrating tablet (OD tablet) to be excellent in disintegrability and have proper hardness. The composite granulated product includes a sugar or a sugar alcohol, a swelling binder, a disintegrating agent, and a highly absorbent excipient.Type: ApplicationFiled: October 4, 2016Publication date: October 4, 2018Applicant: Daido Chemical CorporationInventors: Shunji URAMATSU, Toshinobu UEMURA, Masakazu MORIZANE, Toshio SHIMAMOTO
-
Publication number: 20180280305Abstract: The present invention is a formulation of naproxen having a release profile that provides immediate pain relief equivalent to taking 440 mg (or 2 tablets of 220 mg) naproxen sodium and also extended pain relief for 24 hours. In particular, the present invention is a single solid-dose combining a unique ratio of an immediate release naproxen sodium product with an extended release naproxen sodium layer. More particularly, the present invention is a single bilayer tablet that immediately releases 300-320 mg of naproxen sodium and thereafter gradually releases 450-480 mg of naproxen sodium. This product is capable of providing 24 hours of pain relief when administered as a single bilayer tablet. The single bilayer tablet provides immediate release (IR) of naproxen sodium for initial pain relief from one layer followed by continuous release of the remaining naproxen sodium from the other layer to maintain extended pain relief up to 24 hours.Type: ApplicationFiled: October 9, 2015Publication date: October 4, 2018Inventors: Rachan SIRIHORACHAI, Paul ROSAR
-
Publication number: 20180280306Abstract: Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the drug for the treatment of conditions such as pain.Type: ApplicationFiled: June 6, 2018Publication date: October 4, 2018Inventor: Herriot Tabuteau
-
Publication number: 20180280307Abstract: The present invention relates to high drug load pharmaceutical compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical composition comprising Eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The prior art highlights various technical challenges for formulation development of Eslicarbazepine acetate at lab as well as at industrial scale and offer restrictive and complex approach for resolution of technical challenges. Compositions of Eslicarbazepine acetate prepared as per present invention, wherein disintegrant and/or binder is present in either intra-granular part or in extra-granular part of the composition exhibited desirable technical attributes like comparable dissolution and bioequivalence against reference listed drug.Type: ApplicationFiled: December 16, 2016Publication date: October 4, 2018Inventors: Ravikumar NITHIYANANDAM, Ganesh Vinayak GAT, Dinesh KUMAR, Kamal S. MEHTA, Premchand Dalichandji NAKHAT, Vivek JAIN, Priyank SHARMA, Baibhav JOSHI
-
Publication number: 20180280308Abstract: Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the drug for the treatment of conditions such as pain.Type: ApplicationFiled: June 7, 2018Publication date: October 4, 2018Inventor: Herriot Tabuteau
-
Publication number: 20180280309Abstract: The present patent application relates a process for the production of compressed tablets using specific coated particles, wherein the coating (system) comprises at least one wax and/or at least one fat. Furthermore it relates to compressed (compacted) tablets and as well as to specific coated particles.Type: ApplicationFiled: September 23, 2016Publication date: October 4, 2018Inventors: Jihane ACHKAR, Sylvain DIGUET, Bruno LEUENBERGER, Loni SCHWEIKERT, Olivia VIDONI
-
Publication number: 20180280310Abstract: The embodiments relate to a pharmaceutically effective composition comprising sustained release particles, each sustained release particle comprising a shell and a core, wherein the shell comprises a first material and a second material, the second material comprising a first biodegradable material, wherein the core is enclosed by the shell and the core comprises a drug, wherein the first material is distributed in a matrix of the first biodegradable material, wherein the first material is configured to create holes in the shell and comprises metallic particles, wherein the holes allow the drug to be released to the exterior of the shell through the holes, and wherein the drug comprises a targeting material or targeting molecule that binds to a certain organ, object or a specific site within a body of a human or an animal.Type: ApplicationFiled: June 4, 2018Publication date: October 4, 2018Inventor: Neil S. DAVEY
-
Publication number: 20180280311Abstract: A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.Type: ApplicationFiled: June 5, 2018Publication date: October 4, 2018Applicant: EnGenelC Molecular Delivery Pty LtdInventors: Himanshu BRAHMBHATT, Jennifer MacDiarmid
-
Publication number: 20180280312Abstract: The present invention relates to a packaged probiotic composition which is useful for treating or preventing bacterial colonisation in wounds and tissue. A characteristic feature of the invention is that the probiotic composition contains a probiotic microorganism which is in direct contact with water during storage of the probiotic composition. The invention furthermore pertains to methods of using and producing the probiotic composition.Type: ApplicationFiled: March 22, 2018Publication date: October 4, 2018Inventors: Brian Nielsen, Eric Nielsen, Helene Kähler Hjenner
-
Publication number: 20180280313Abstract: A nanostructured biocompatible wafer for drug delivery to a tissue. The wafer contains a tissue-reactive mucoadhesive polymer and a mesh formed of a plurality of polymer fibers. Also provided is a method for treating an ocular surface disease, disorder, or infection using the nanostructured biocompatible wafer. Additionally, an injectable sustained-release formulation for treating an ocular disorder is disclosed. The formulation includes a drug contained within a plurality of microparticles formed of a biodegradable polymer and are coated with a tissue-reactive compound. Further provided is a method for treating an ocular disorder by injecting the microparticulate sustained release formulation.Type: ApplicationFiled: April 3, 2018Publication date: October 4, 2018Inventors: Shikha P. Barman, Moli Liu, Koushik Barman, Kevin L. Ward, Brendan Hackett
-
Publication number: 20180280314Abstract: Methods of producing a Hydrophilic Homeopathic Aqueous Substance Active (HASA)-gel matrix, include the steps of: (a) combining a homeopathic compound and an uninhibited aqueous composition to produce a HASA; (b) combining the HASA with at least one hydrophilic gelling agent; and (c) thereafter, forming the hydrophilic HASA-gel matrix by use of at least one of a thickening agent, a crosslinking agent, or a polymerization agent.Type: ApplicationFiled: June 6, 2018Publication date: October 4, 2018Inventor: Nancy Josephine POLICH
-
Publication number: 20180280315Abstract: The present invention provides a star-shaped acrylic block polymer having a star-shaped structure in which at least three chain polymer portions radiate from a mercapto group situated at the center, wherein (meth)acrylic acid alkyl ester structural units having 7-17 carbon atoms account for 30-99.9% by mass of whole structural units of the star-shaped acrylic block polymer, and at least one of the chain polymer portions has a copolymer structure of polymerizable monomers containing a (meth)acrylic acid alkyl ester having 7-17 carbon atoms and a weakly basic monomer; and a medical patch containing an adhesive composition containing a salt of a basic drug and the star-shaped acrylic block polymer as an adhesive that exhibits high drug efficacy, that does not cause a decrease in adhesive property of an adhesive base due to an additive, and that causes less skin irritation.Type: ApplicationFiled: September 30, 2016Publication date: October 4, 2018Applicants: TEIKOKU SEIYAKU CO., LTD., NIPPON SHOKUBAI CO., LTD.Inventors: Satoshi KAWAKAMI, Manabu SOGABE, Taiki SHIBATA, Yasushi HORIKAWA, Hiroaki HASEGAWA
-
Publication number: 20180280316Abstract: In one embodiment, a transdermal patch includes a substrate and a layer of pressure-sensitive adhesive provided on the substrate, the pressure-sensitive adhesive comprising a blend of an adhesive compound and a carrier-drug compound, the carrier-drug compound comprising a drug transport compound and a drug that is to be delivered to the skin of a subject, wherein the drug transport compound transports the drug through the pressure-sensitive adhesive to the skinType: ApplicationFiled: March 28, 2018Publication date: October 4, 2018Inventors: Howard S. Rosing, Yadong Wang
-
Publication number: 20180280317Abstract: The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of an isomer or analog of monoterpene or sesquiterpene (or its derivative), such as an isoperillyl alcohol. The present invention also provides for a method of treating a disease comprising the step of administering to a patient a therapeutically effective amount of a derivative of an isomer or analog of monoterpene or sesquiterpene, such as an isoperillyl alcohol carbamate. The derivative may be an isoperillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.Type: ApplicationFiled: June 4, 2018Publication date: October 4, 2018Inventors: Thomas Chen, Daniel Levin, Satish Pupalli, Daniel Anthony Dickman
-
Publication number: 20180280318Abstract: The present invention provides a system enabling the oral delivery of therapeutics derived from polyunsaturated fatty acids (PUFAs), their metabolites and derivatives, including, eicosanoids, prostaglandins, prostacyclins, leukotrienes, resolvins, endocannabinoids, thromboxanes, epoxyeicosa-trienoic acids (EETs), hydroxyeicostetraenoic acids (HETEs), and CMX-020. The delivery system includes a vehicle comprising a purified docosahexaenoic acid (DHA) in triglyceride or ester form; a purified eicosapentaenoic acid (EPA) in triglyceride or ester form; a combination of DHA, EPA in either triglyceride or ester forms; or a modified DHA, EPA, or omega-3 fatty acid analog; and optionally, an antioxidant, a surfactant, a solubilizer, a stabilizer, a lubricant, or a pH/tonicity adjustment agent.Type: ApplicationFiled: May 3, 2016Publication date: October 4, 2018Inventors: Lane Brostrom, Henry Bordas-Murphy, John R. Falck
-
Publication number: 20180280319Abstract: The present invention provides novel methods of treating triple-negative breast cancer (TNBC). In certain embodiments, the methods of the invention do not require the use of ionizing radiation therapies. In other embodiments, the methods of the invention do not harm non-cancerous cells.Type: ApplicationFiled: April 4, 2018Publication date: October 4, 2018Inventors: ADEBOYE ADEJARE, ISABELLE MERCIER, ZEYNEP ATES-ALAGOZ
-
Publication number: 20180280320Abstract: Derivatives of 6-shogaol are described herein. Also described herein are methods of preparing the derivatives, as well as methods of using the derivatives to activate Nrf2 and to treat diseases associated with inflammation and/or oxidative stress.Type: ApplicationFiled: March 23, 2018Publication date: October 4, 2018Applicants: North Carolina Agricultural and Technical State University, North Carolina Central UniversityInventors: Shengmin Sang, Yingdong Zhu, TinChung Leung
-
Publication number: 20180280321Abstract: This disclosure describes pharmaceutical compositions and methods that involve the use of a polyhydroxyanthraquinone to inhibit quorum sensing in a microbe. In some embodiments, the polyhydroxyanthraquinone may be effective to antagonize AgrA function in a microbe. In other embodiments, the polyhydroxyanthraquinone may be effective for prophylactic and/or therapeutic treatment of a skin and soft tissue infection (SSTI) of a subject by a microbe. In still other embodiments, the polyhydroxyanthraquinone may be effective to reduce, limit progression, ameliorate, or resolve, to any extent, a symptom or clinical sign of infection by a microbe.Type: ApplicationFiled: March 11, 2016Publication date: October 4, 2018Inventor: Pamela R. Hall
-
Publication number: 20180280322Abstract: Sugar alcohol-free formulations of fingolimod. Compositions of fingolimod, salts thereof, or esters thereof that lack sugar alcohols are disclosed. The composition may include a water-soluble filler and a water-insoluble filler, in addition to other common excipients. In some examples, the water-soluble filler is glycine and the water-insoluble filler is dibasic calcium phosphate dihydrate as fillers. In some examples, the water-soluble filler and water-insoluble filler are present in equal concentrations. The compositions disclosed here may be used to make immediate release dosage forms containing fingolimod hydrochloride.Type: ApplicationFiled: August 8, 2016Publication date: October 4, 2018Applicant: Mylan Inc.Inventors: Sarat C Chattaraj, Zhi Liu, John Kirsch
-
Publication number: 20180280323Abstract: The chronic use of ?-adrenergic inverse agonists such as nadolol, carvedilol, and ICI-118,551 provides an improved method for the treatment of mucus hypersecretion in subjects with such mucus hypersecretion or at risk of developing mucus hypersecretion, especially in subjects attempting smoking cessation. One aspect of a method according to the present invention is a method of preventing or controlling mucus hypersecretion in the respiratory tract comprising administering a therapeutically effective quantity of a ?-adrenergic inverse agonist to a subject with mucus hypersecretion or at risk of mucus hypersecretion. Another aspect of a method according to the present invention is a method of treating or preventing a disease or condition characterized by mucus hypersecretion comprising administering a therapeutically effective quantity of a ?-adrenergic inverse agonist to a subject with such a disease or condition or at risk of contracting such a disease or condition.Type: ApplicationFiled: June 7, 2018Publication date: October 4, 2018Inventors: Richard A. BOND, Mitchell GLASS
-
Publication number: 20180280324Abstract: The current invention relates to treatment of drug resistant melanoma with histone deacetylase inhibitors (HDACi). In particular the invention relates to BRAF and NRAS mutated melanoma and that have acquired resistance to MAPK pathway inhibitors, for example due to previous treatment with such MAPK pathway inhibitors. The invention discloses HDACi and/or MAPK pathway inhibitors for use in such treatment and treatment regimens using such inhibitors.Type: ApplicationFiled: September 8, 2016Publication date: October 4, 2018Inventors: Liqin WANG, Rodrigo LEITE DE OLIVEIRA, Rene BERNARDS
-
Publication number: 20180280325Abstract: The present technology is related to reducing or treating neurological swelling and related conditions with SUR1-TRPM4 channel inhibitors. In some embodiments, the methods include: reducing late neurological deterioration or preventing death, reducing cerebral midline shift, reducing the degree of disability in a subject, counteracting blood glucose levels in a subject receiving a SUR1-TRPM4 channel inhibitor, preventing brain swelling, monitoring liver enzyme activity along with treating injury or conditions related to CNS edema, or monitoring cardiac activity along with treating injury or conditions related to CNS edema.Type: ApplicationFiled: October 7, 2016Publication date: October 4, 2018Applicant: BIOGEN CHESAPEAKE LLCInventor: Sven Martin JACOBSON
-
Publication number: 20180280326Abstract: The present invention provides a novel medicament for preventing or inhibiting acute kidney injury, the medicament comprising, as an active ingredient, an angiotensin II receptor type 2 agonist or a pharmacologically acceptable salt thereof, and being used for treatment or prevention of acute kidney injury. Also, the present invention provides a novel method for preventing or inhibiting acute kidney injury, the method comprising administering, to a patient, an effective amount of an angiotensin II receptor type 2 agonist or a pharmacologically acceptable salt thereof in combination with an anticancer agent and/or an antitumor agent.Type: ApplicationFiled: October 5, 2016Publication date: October 4, 2018Inventors: Kenji Kangawa, Hiroshi Hosoda, Takashi Nojiri
-
Publication number: 20180280327Abstract: The present invention relates to intervertebral disc-related pain, such as low back pain, chronic low back pain, neck pain, chronic neck pain and coccygodynia. A composition for use in the treatment of intervertebral disc-related pain is provided. The composition comprises lactic acid, or a pharmaceutically acceptable salt thereof. The composition is administered into a disc space comprising the nucleus pulposus of an intervertebral disc.Type: ApplicationFiled: May 31, 2018Publication date: October 4, 2018Applicant: STAYBLE THERAPEUTICS ABInventor: Kjell Olmarker
-
Publication number: 20180280328Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.Type: ApplicationFiled: June 13, 2018Publication date: October 4, 2018Inventors: Raphael DARTEIL, Rémy HANF, Dean HUM, Ingrid DUFOUR
-
Publication number: 20180280329Abstract: The present invention relates to methods and compositions used to reduce or prevent organ, tissue and cellular damage induced by irradiation exposure, such as radiodermatitis and radio mucositis. The compositions according to the invention comprise one or more inhibitors of plasminogen or one or more inhibitors of a component of the plasminogen activating pathway.Type: ApplicationFiled: September 22, 2016Publication date: October 4, 2018Applicant: OMNIO ABInventors: Tor NY, Mahsa FALLAH, Malgorzata WILCZYNSKA, Michael BLOMQUIST, Mikael JOHANSSON
-
Publication number: 20180280330Abstract: Disclosed herein are sustained release Liothyronine oral capsule formulations, methods of making the formulations and use to treat hypothyroidism, a thyroid deficient disease state, or thyroid dysfunction.Type: ApplicationFiled: March 30, 2018Publication date: October 4, 2018Inventors: Shabnam N. Sani, Hamid Bakhteyar
-
Publication number: 20180280331Abstract: A composition for enhancing neuroregeneration of the sciatic nerve in a mammal is provided that includes medicinally effective amounts of glycine, glutamine, and phenylalanine. In some embodiments, the glutamine can be L-glutamine and the phenylalanine can be D, L-phenylalanine. A method for treating sciatic pain is also included.Type: ApplicationFiled: April 4, 2018Publication date: October 4, 2018Inventor: ALICIA MARIE WIGGINS
-
Publication number: 20180280332Abstract: The invention pertains to a method for improving or promoting equilibrioception or coordination and balance in a healthy subject, comprising administration of: (i) ?-3 polyunsaturated fatty acid (LCPUFA) selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA); (ii) one of more of uridine, cytidine and/or an equivalent thereof, including salts, phosphates, acyl derivatives and/or esters; and (iii) free leucine, to said healthy subject. The invention also pertains to a composition for use in such a method.Type: ApplicationFiled: October 24, 2016Publication date: October 4, 2018Applicant: N.V. NutriciaInventors: Mattheus Cornelis DE WILDE, Danielle Stefanie COUNOTTE
-
Publication number: 20180280333Abstract: Novel methods for isolating fish roe/egg extracts, notably a coagulum and a sediment extract, enriched in phospholipids and omega-3 fatty acids are described. Novel compositions comprising omega-3 polyunsaturated fatty acids and micronutrients, which may be used for the management of neurological conditions such as ADD-ADHD, autism, cognitive impairment, and mood disorders are also described. These compositions are homogenous compositions comprising effective amounts of omega-3 fatty acids in microencapsulated or emulsified form, and/or from the sediment extract from fish roe/egg, vitamin B6, magnesium, zinc and copper, and may further comprise additional ingredients such as folic acid (e.g., L-methyl folate) and gamma-linolenic acid (GLA).Type: ApplicationFiled: March 29, 2018Publication date: October 4, 2018Inventors: ADRIEN BEAUDOIN, LUC BEAUDOIN
-
Publication number: 20180280334Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: ApplicationFiled: June 4, 2018Publication date: October 4, 2018Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20180280335Abstract: Provided herein are methods of treating an IDH mutant cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an all-trans retinoic acid (ATRA). In some embodiments, the methods increase an NK-cell-mediated immune response and/or a T cell-mediated immune response to the cancer. In some embodiments, the cancer is a glioma or a chondrosarcoma. In some embodiments, the expression of one or more NKG2D ligands (e.g., ULBP1 and ULBP3) is increased in a tumor microenvironment of the cancer. In some embodiments, CCL2 production, the number of NK cells, and/or apoptosis of tumor cells is increased in a tumor microenvironment of the cancer. In some embodiments, the subject has an IDH1 mutation at arginine 132 or an IDH2 mutation at arginine 172. In some embodiments, method reduces growth of a tumor.Type: ApplicationFiled: March 28, 2018Publication date: October 4, 2018Inventors: Ndukaku Amankulor, Aparna Rao